Mueller Industries Inc. Common Stock vs Novavax Inc — how do they compare? Mueller Industries Inc. Common Stock trades at $60.63 (market cap $13.44B), while Novavax Inc trades at $12.41 (market cap $2.08B). The key difference: Mueller Industries Inc. Common Stock is far larger — about 6.5× Novavax Inc's market cap, and Mueller Industries Inc. Common Stock pays a 1.15% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mueller Industries Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| MLI | NVAX | |
|---|---|---|
Market Cap | $13.44B | $2.08B |
Volume | 1,191,194 | 8,501,139 |
Sector | Industrials | Health |
52-Week High | $70.42 | $12.82 |
52-Week Low | $49.29 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $12.05B | $1.66B |
Dividend Yield | 1.15% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Mueller Industries, Inc. is a US industrial manufacturer and the only vertically integrated producer of copper tube, fittings, and brass rod and forgings in North America, operating through its Piping Systems, Industrial Metals, and Climate segments.
Read more on MLI →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →